microbiolog
statu
experiment
anim
critic
influenc
valid
reproduc
research
data
ensur
anim
free
infecti
agent
might
interfer
research
reduc
number
anim
requir
studi
contribut
substanti
anim
welfar
effect
health
monitor
program
crucial
assess
health
statu
research
subject
valid
infect
control
measur
numer
public
provid
guidanc
establish
health
monitor
program
tailor
rodent
feder
european
laboratori
anim
scienc
associ
publish
detail
recommend
constitut
common
standard
health
monitor
report
procedur
europ
current
inform
preval
infecti
agent
must
made
regularli
avail
standard
health
monitor
recommend
kept
date
exampl
preval
data
use
develop
list
agent
test
help
determin
necessari
frequenc
test
laboratori
anim
coloni
inform
preval
infect
may
also
contribut
better
understand
epidemiolog
monitor
viral
agent
sever
type
bacteria
mycoplasma
pulmoni
larg
reli
detect
specif
antibodi
produc
infect
mani
institut
sent
rodent
serum
sampl
laboratori
test
present
survey
data
regard
preval
antibodi
virus
pulmoni
sera
mice
rat
western
european
institut
data
collect
serolog
test
carri
laboratori
period
evalu
current
preval
rate
virus
bacterium
mycoplasma
pulmoni
author
retrospect
survey
serolog
data
obtain
laboratori
mice
rat
hous
western
european
institut
serum
sampl
submit
author
institut
test
januari
june
preval
infect
defin
percentag
test
sampl
yield
posit
result
specif
agent
mice
commonli
detect
infecti
agent
murin
noroviru
preval
mous
hepat
viru
mous
rotaviru
parvovirus
rat
parvovirus
pulmoni
preval
infecti
agent
rodent
parvoviru
infect
could
attribut
mous
parvoviru
mice
rat
minut
viru
kilham
rat
viru
rat
data
suggest
import
uptod
anim
health
monitor
program
stimul
scientif
commun
improv
microbiolog
qualiti
laboratori
rodent
emphas
survey
data
collect
retrospect
test
request
client
biodoc
client
select
anim
test
indic
infect
test
therefor
data
repres
random
popul
nevertheless
data
taken
larg
number
serum
sampl
institut
believ
result
provid
good
reflect
current
health
statu
laboratori
mice
rat
western
europ
survey
data
serum
sampl
test
biodoc
hannov
germani
januari
june
sampl
suppli
differ
institut
includ
univers
research
center
industri
facil
breed
compani
diagnost
laboratori
institut
locat
eight
european
countri
austria
denmark
germani
finland
franc
sweden
switzerland
unit
kingdom
sampl
submit
german
institut
number
sampl
test
infecti
agent
vari
accord
client
request
rang
mice
rat
defin
preval
particular
infect
percentag
test
sampl
antibodi
associ
agent
detect
littl
background
inform
provid
serum
sampl
case
detail
suppli
name
address
sender
anim
speci
agent
test
inform
concern
coloni
strain
age
gender
anim
sera
deriv
could
therefor
evalu
gener
presenc
agentspecif
antibodi
determin
use
valid
inhous
immunofluoresc
assay
ifa
hemagglutin
inhibit
hai
assay
primari
test
method
necessari
inhous
commerci
avail
enzymelink
immunosorb
assay
elisa
use
confirmatori
test
method
tabl
carri
inhous
assay
accord
publish
protocol
commerci
elisa
charl
river
laboratori
wilmington
carri
accord
manufactur
standard
protocol
parvoviru
infect
mice
rat
diagnos
use
ifa
minut
viru
mice
kilham
rat
viru
respect
use
antigen
ifa
measur
crossreact
antibodi
variou
parvovirus
target
highli
conserv
nonstructur
viral
protein
therefor
ifa
yield
posit
result
test
carri
differenti
among
serotyp
done
hai
assay
minut
viru
mice
kilham
rat
viru
toolan
viru
rat
parvoviru
recombin
viral
elisa
known
serotyp
assay
target
viral
capsid
protein
serotypespecif
accord
serolog
data
obtain
preval
infecti
agent
mice
follow
descend
order
preval
serolog
assay
invalu
detect
antibodi
virus
type
bacteria
pulmoni
laboratori
anim
commonli
use
assay
includ
ifa
elisa
hai
assay
immunoblot
assay
recent
multiplex
fluoresc
immunoassay
method
use
must
select
care
method
may
differ
sensit
specif
unexpect
result
alway
confirm
second
method
second
laboratori
monitor
addit
anim
present
survey
ifa
gener
use
primari
test
method
hai
assay
use
primari
test
method
detect
k
viru
mice
elisa
use
confirmatori
test
elisa
hai
assay
use
secondari
test
distinguish
serotyp
parvovirus
tabl
ifa
highli
sensit
like
elisa
hai
assay
detect
crossreact
antibodi
close
relat
virus
thu
ifa
use
primari
screen
broader
reactiv
attribut
use
virusinfect
cell
antigen
contain
nonstructur
structur
viral
protein
ifa
subject
specif
nonspecif
reactiv
morpholog
locat
fluoresc
evalu
differenti
specif
non
specif
reaction
main
disadvantag
ifa
interpret
result
subject
depend
experi
observ
like
ifa
elisa
highli
sensit
often
use
primari
test
howev
nonspecif
crossreact
irrelev
antibodi
test
sera
antigen
use
caus
assay
produc
fals
posit
result
crossreact
reduc
use
highli
purifi
antigen
prepar
recombin
technolog
hai
assay
restrict
virus
hemagglutinin
protein
bind
red
blood
cell
surfac
hai
test
lack
sensit
highli
specif
use
differenti
close
relat
virus
rodent
parvovirus
case
ifa
interpret
hai
test
result
subject
serolog
survey
suggest
mani
infect
elimin
rel
low
preval
laboratori
rodent
maintain
western
europ
wherea
infect
highli
preval
mice
preval
infect
detect
mnv
mous
hepat
viru
mous
rotaviru
parvo
virus
rat
parvovirus
pulmoni
preval
rodent
parvoviru
infect
could
attribut
mous
parvoviru
mice
rat
minut
viru
kilham
rat
viru
rat
sever
parvoviru
infect
mice
rat
could
attribut
singl
serotyp
mean
hai
assay
recombin
elisa
might
result
lack
specif
assay
simultan
infect
two
parvovirus
infect
yet
unknown
parvoviru
note
preval
rat
parvovirus
particular
rat
minut
viru
might
overestim
survey
larg
number
posit
serum
sampl
n
came
singl
rat
coloni
infect
viru
hand
specul
mani
serum
sampl
submit
test
taken
coloni
presum
clean
test
aim
confirm
seroneg
statu
coloni
experi
monitor
agent
known
endem
popul
usual
done
infrequ
therefor
true
preval
rate
commonli
occur
agent
except
rat
parvovirus
may
higher
report
caution
must
also
exercis
interpret
serolog
result
pulmoni
anim
may
fals
seroposit
owe
infect
murin
mycoplasma
arthritidi
crossreact
pulmoni
antigen
natur
infect
mycoplasma
speci
mice
rat
rare
report
howev
sampl
test
posit
ifa
use
pulmoni
antigen
yield
strong
fluoresc
signal
analys
therefor
consid
mani
seroposit
result
attribut
infect
pulmoni
exact
comparison
preval
data
recent
studi
western
europ
north
america
possibl
studi
differ
definit
preval
indic
percentag
survey
facil
particular
infect
detect
percentag
sampl
group
serum
sampl
taken
anim
singl
popul
least
one
serum
sampl
test
posit
percentag
posit
individu
serum
sampl
studi
nevertheless
studi
show
similar
find
regard
rank
preval
viral
infect
current
mous
hepat
viru
parvovirus
particular
mous
parvoviru
mous
rotaviru
among
preval
viral
infect
mice
parvovirus
cardiovirus
pneumonia
viru
mice
coronavirus
preval
rat
occurr
mnv
mice
address
abovement
survey
agent
recent
identifi
studi
indic
preval
mnv
greater
preval
virus
mice
notabl
find
preval
rate
almost
ident
recent
survey
found
antibodi
mnv
mous
sera
test
preval
infect
demonstr
import
health
monitor
program
laboratori
anim
facil
stimul
scientif
commun
improv
microbiolog
qualiti
laboratori
rodent
increas
use
transgen
anim
vari
immunocompet
exchang
anim
biolog
materi
among
institut
creat
risk
transfer
infecti
agent
heighten
import
screen
incom
anim
biolog
materi
presenc
infecti
agent
preval
data
consid
current
health
monitor
program
indic
risk
infect
use
aid
develop
list
agent
test
help
determin
necessari
frequenc
test
laboratori
anim
coloni
costconsci
reason
approach
would
monitor
frequent
quarterli
exampl
preval
highrisk
agent
mnv
mous
hepat
viru
parvovirus
mous
rotaviru
mice
less
frequent
annual
semiannu
exampl
rare
lowerrisk
agent
also
consid
effect
agent
would
ongo
research
research
staff
final
discoveri
new
agent
mnv
highlight
need
regular
review
updat
health
monitor
program
